Announcement • Jun 30
Nexalin Technology, Inc., Annual General Meeting, Aug 11, 2026 Nexalin Technology, Inc., Annual General Meeting, Aug 11, 2026. Announcement • Jun 16
Nexalin Technology Announces Acceptance of Two Clinical Abstracts for Presentation At 2026 Nyc Neuromodulation Conference Nexalin Technology, Inc. announced that two clinical abstracts evaluating Nexalin’s proprietary DIFS™ 15 mA, 77.5 Hz treatment platform have been accepted for presentation at the 2026 NYC Neuromodulation Conference. The accepted abstracts are titled: 1) “Transcranial Alternating Current Stimulation for the Treatment of Anxiety: Preliminary Results from an Open-Label Pilot Clinical Trial” 2) “Transcranial Alternating Current Stimulation for Comorbid Anxiety and Insomnia: Preliminary Findings on Insomnia and Quality of Life from an Open-Label Pilot Trial”. The accepted abstracts are based on data from the Company’s recently completed 8-week, single-center, prospective, clinical trial conducted at the Institute of Psychiatry, Hospital das Clínicas, University of São Paulo. Adults with generalized anxiety disorder and comorbid insomnia received 20 sessions of Nexalin’s proprietary 15 mAmp deep-brain frequency stimulation over four weeks, followed by a four-week follow-up period. Each 40-minute session was administered using the Nexalin DIFS™ device at 15 mA and 77.5 Hz. Key highlights from the accepted abstracts include: 77.8% anxiety response rate at end of treatment: Anxiety response rates reached 77.8% at Session 20. Rapid anxiety improvement: Hamilton Anxiety Rating Scale (HAM-A) scores decreased by 14.73 points by Session 5. Durable anxiety benefit: HAM-A scores decreased by 18.30 points by Session 20, with reductions observed at 8-week post-treatment follow-up. Depressive symptom improvement: Hamilton Depression Rating Scale (HAMD) scores decreased by 9.90 points by Session 20. High depressive symptom response and remission: HAMD response and remission rates both reached 66.7% at the end of treatment. Sustained insomnia improvement: Pittsburgh Sleep Quality Index (PSQI) scores improved significantly at the end of treatment and remained significantly improved at 8-week follow-up, with large effect sizes reported. Quality-of-life improvement: Overall quality of life improved significantly at the end of treatment, with favorable directional trends across additional quality-of-life domains. Favorable tolerability profile: No serious adverse events, seizures or manic/hypomanic switches were reported. The NYC Neuromodulation Conference brings together clinicians, researchers, engineers, entrepreneurs and industry participants focused on the development and application of neuromodulation technologies. Nexalin believes the acceptance of these abstracts provides an important opportunity to further communicate the clinical and scientific rationale for its DIFS™ platform to a specialized audience focused on next-generation neurostimulation. Nexalin also believes the data may support broader commercial initiatives across international markets, including Brazil, where the study was conducted and where the Company is preparing for a potential product launch. Unlike many neurostimulation technologies that are based on incremental modifications to existing approaches, Nexalin’s platform is designed to deliver proprietary high-power frequency-based stimulation that the Company believes may penetrate deeper brain regions associated with mood, sleep and other neuropsychiatric disorders. Nexalin believes this differentiated approach may provide a meaningful competitive advantage as the Company advances its FDA De Novo regulatory pathway, clinical development programs and commercialization strategy. The Nexalin Gen-2 15 milliamp neurostimulation device has been approved in China, Brazil, Oman and Israel. Announcement • Jun 11
Nexalin Technology, Inc. Reports Compelling Clinical Trial Results in Brazil to Support Product Launch Nexalin Technology Inc. announced the successful completion of an 8-week, single-center, prospective, open-label clinical trial evaluating Nexalin's proprietary 15 milliamp (mA), 77.5 Hz neurostimulation protocol in adults with generalized anxiety disorder and comorbid insomnia. The clinical trial was conducted at the Institute of Psychiatry, Hospital das Cli´nicas, University of Sa~o Paulo. Participants received 20 sessions of transcranial alternating current stimulation over four weeks, followed by a four-week follow-up period. Each 40-minute session was administered using the Nexalin DIFSTM device at 15 mA and 77.5 Hz. The completed trial demonstrated rapid, large-magnitude and durable improvements across multiple high-burden neuropsychiatric domains, including anxiety, depressive symptoms, insomnia and quality of life. Improvements were observed early in the treatment course, continued through the end of treatment, and were maintained at 8-week follow-up. Key results from the completed pilot trial include: 77.8% anxiety response rate at end of treatment: Anxiety response rates reached 77.8% at Session 20. Rapid anxiety improvement: Hamilton Anxiety Rating Scale (HAM-A) scores decreased by 14.73 points by Session 5. Durable anxiety benefit: HAM-A scores decreased by 18.30 points by Session 20, with reductions maintained at 8-week follow-up. Depressive symptom improvement: Hamilton Depression Rating Scale (HAMD) scores decreased by 9.90 points by Session 20. High depressive symptom response and remission: HAMD response and remission rates both reached 66.7% at the end of treatment. Sustained insomnia improvement: Pittsburgh Sleep Quality Index (PSQI) scores improved significantly at the end of treatment and remained significantly improved at 8-week follow-up, with large effect sizes reported. Quality-of-life improvement: Overall quality of life improved significantly at the end of treatment, with favorable directional trends across additional quality-of-life domains. Favorable tolerability profile: No serious adverse events, seizures or manic/hypomanic switches were reported. 
